AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 May 2022
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)Product type:GuidanceProgramme:Medical technologies guidancePublished: 25 July 2011
Avelumab for treating metastatic Merkel cell carcinoma (TA517)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 April 2021Published: 11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 April 2021
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2017
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2014
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2018
Digital technologies for the detection of melanoma (MIB311)Product type:AdviceProgramme:Medtech innovation briefingPublished: 1 November 2022
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2013
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 February 2014
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Endoscopic radical inguinal lymphadenectomy (IPG398)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 June 2011
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 April 2024
GatewayC: Improving early detection of cancer through e-learning for primary careProduct type:Shared learningPublished: 31 January 2019
Improving outcomes for people with skin tumours including melanoma (CSG8)Product type:GuidanceProgramme:Cancer service guidelineLast updated: 25 May 2010Published: 22 February 2006
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2012
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Melanoma: assessment and management (NG14)Product type:GuidanceProgramme:NICE guidelineLast updated: 27 July 2022Published: 29 July 2015
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 March 2021
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 February 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2016
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referralProduct type:Shared learningPublished: 8 January 2017
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2022
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 7 October 2015
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 February 2006
Skin cancer (QS130)Product type:Quality standardLast updated: 24 January 2024Published: 21 September 2016
Skin cancer prevention (PH32)Product type:GuidanceProgramme:Public health guidelineLast updated: 9 February 2016Published: 26 January 2011
Sunlight exposure: risks and benefits (NG34)Product type:GuidanceProgramme:NICE guidelinePublished: 9 February 2016
Sun Safe Schools Accreditation – National intervention programmeProduct type:Shared learningPublished: 8 April 2021
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Symptomatic Breast Referral Resource Suite: Enhancing the Suspected Cancer Recognition and Referral ProcessProduct type:Shared learningPublished: 10 November 2020
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2015Published: 12 December 2012
Vismodegib for treating basal cell carcinoma (TA489)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2017
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)Product type:GuidanceProgramme:Diagnostics guidancePublished: 11 November 2015